Impact of sphingomyelin levels on coronary heart disease and left ventricular systolic function in humans

Nutrition & Metabolism

Xian-Cheng Jiang¹  Jason M Lazar³  Junbo Ge²  Yunzeng Zou²  Aijun Sun²  Xueying Chen² 

[1] Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA;Institute of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, PR China;Division of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA

关键词: lipids;    coronary heart disease;    left ventricular ejection fraction;    sphingomyelin;   

Others  :  821377
DOI  :  10.1186/1743-7075-8-25

 received in 2011-01-30, accepted in 2011-04-26,  发布年份 2011

【 摘 要 】

Sphingomyelin (SM) is an abundant phospholipid in cell membranes and in lipoproteins. In human plasma, SM is mainly found in atherogenic lipoproteins; therefore, higher levels of SM may promote atherogenesis. We investigated the relations between plasma SM levels and the presence of angiographic coronary heart disease (CHD) and left ventricular systolic dysfunction. We studied 732 patients referred for coronary angiography. Median SM levels were higher among patients with CHD and in those with LV systolic dysfunction (LVEF<50%) than in patients without CHD or LV dysfunction. SM levels were significantly correlated with fibrinogen levels, diabetes, apoB, and triglyceride levels. On multivariate analyses, higher median SM levels were associated with a higher risk of CHD and lower LV ejection fraction. The pro-atherogenic property of plasma SM might be related to 1) CHD; 2) LV systolic dysfunction; and 3) metabolism of apoB-containing or triglyceride-rich lipoproteins.

【 授权许可】

   
2011 Chen et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Nilsson A, Duan RD: Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 2006, 47:154-171.
• [2]Subbaiah PV, Davidson MH, Ritter MC, Buchanan W, Bagdade JD: Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. Atherosclerosis 1989, 79:157-166.
• [3]Rodriguez JL, Ghiselli GC, Torreggiani D, Sirtori CR: Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1. Chemical composition of very low density lipoproteins in rabbits. Atherosclerosis 1976, 23:73-83.
• [4]Zilversmit DB, Mc CE, Jordan PH, Henly WS, Ackerman RF: The synthesis of phospholipids in human atheromatous lesions. Circulation 1961, 23:370-375.
• [5]Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
• [6]Williams KJ, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9:471-474.
• [7]Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I: Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996, 98:1455-1464.
• [8]Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I: Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008, 28:1723-1730.
• [9]Jeong T, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X: Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998, 101:905-912.
• [10]Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
• [11]Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, Lu S, Jiang XC: Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005, 280:10284-10289.
• [12]Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD: Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004, 110:3465-3471.
• [13]Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR: Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20:2614-2618.
• [14]Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, Bickel C, Lackner KJ, Meyer J, Rupprecht HJ, Jiang XC: Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006, 3:5. BioMed Central Full Text
• [15]Nelson JC, Jiang XC, Tabas I, Tall A, Shea S: Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006, 163:903-912.
• [16]Yeboah J, McNamara C, Jiang XC, Tabas I, Herrington DM, Burke GL, Shea S: Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:628-633.
• [17]Hojjati MR, Jiang XC: Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J Lipid Res 2006, 47:673-676.
• [18]Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo MS, Cao G, Wadgaonkar R, Jiang XC: Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol 2008, 28:1519-1526.
• [19]Liu JC, Wang DM, Qian JN, Li YG, Wang LJ, Jiang XL, Zhai LL, Lu J, Qi P: [Changes of nitric oxide and endothelin serum level after carotid balloon denudation or stent assisted angioplasty: an experimental and clinical observation]. Zhonghua Wai Ke Za Zhi 2009, 47:423-426.
• [20]Lozanski G, Berthier F, Kushner I: The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen. Biochem J 1997, 328(Pt 1):271-275.
• [21]Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
• [22]Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA: Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 1998, 273:11313-11320.
• [23]Oral H, Dorn GW, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997, 272:4836-4842.
• [24]Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F: Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes. Am J Physiol Cell Physiol 2002, 282:C1339-1347.
• [25]Cailleret M, Amadou A, Andrieu-Abadie N, Nawrocki A, Adamy C, Ait-Mamar B, Rocaries F, Best-Belpomme M, Levade T, Pavoine C, Pecker F: N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation 2004, 109:406-411.
• [26]Pavoine C, Pecker F: Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009, 82:175-183.
• [27]Mrnka L, Novakova O, Pelouch V, Novak F: Phospholipid composition in the rat heart exposed to pressure overload from birth. Physiol Res 1996, 45:83-85.
• [28]Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, Jiang XC: Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res 2009, 105:295-303.
• [29]Fan Y, Shi F, Liu J, Dong J, Bui HH, Peake DA, Kuo MS, Cao G, Jiang XC: Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:2114-2120.
• [30]Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
• [31]Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I: The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 1998, 273:18250-18259.
• [32]Schlitt A, Hojjati MR, von Gizycki H, Lackner KJ, Blankenberg S, Schwaab B, Meyer J, Rupprecht HJ, Jiang XC: Serum sphingomyelin levels are related to the clearance of postprandial remnantlike particles. J Lipid Res 2005, 46:196-200.
• [33]Fan Y, Shi F, Liu J, Dong J, Bui HH, Peake DA, Kuo MS, Cao G, Jiang XC: Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis. Arterioscler Thromb Vasc Biol 2010.